| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 50 | 2020 | 222 | 7.430 |
Why?
|
| Skin | 25 | 2018 | 222 | 3.250 |
Why?
|
| Skin Diseases, Vascular | 7 | 2019 | 11 | 1.830 |
Why?
|
| Immunohistochemistry | 28 | 2019 | 593 | 1.730 |
Why?
|
| Exanthema | 4 | 2018 | 20 | 1.690 |
Why?
|
| Humans | 133 | 2020 | 34474 | 1.320 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2019 | 168 | 1.300 |
Why?
|
| Telangiectasis | 3 | 2019 | 5 | 1.270 |
Why?
|
| Skin Diseases | 10 | 2017 | 148 | 1.270 |
Why?
|
| Collagen Type I | 2 | 2019 | 48 | 1.220 |
Why?
|
| Diagnosis, Differential | 31 | 2019 | 540 | 1.220 |
Why?
|
| Dermatology | 11 | 2017 | 164 | 1.080 |
Why?
|
| Xanthomatosis | 2 | 2017 | 3 | 1.070 |
Why?
|
| Biopsy, Needle | 11 | 2019 | 100 | 1.050 |
Why?
|
| Middle Aged | 61 | 2020 | 12703 | 0.960 |
Why?
|
| Pathology | 7 | 2013 | 17 | 0.930 |
Why?
|
| Female | 74 | 2020 | 21490 | 0.920 |
Why?
|
| Hemangioendothelioma | 5 | 2015 | 11 | 0.870 |
Why?
|
| Mycosis Fungoides | 6 | 2017 | 12 | 0.870 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2018 | 42 | 0.850 |
Why?
|
| Male | 61 | 2020 | 20697 | 0.830 |
Why?
|
| Tattooing | 3 | 2017 | 7 | 0.830 |
Why?
|
| Erythema | 6 | 2019 | 25 | 0.820 |
Why?
|
| Pellagra | 2 | 2016 | 3 | 0.810 |
Why?
|
| Melanoma | 10 | 2014 | 169 | 0.810 |
Why?
|
| Lichen Sclerosus et Atrophicus | 2 | 2017 | 10 | 0.780 |
Why?
|
| Adult | 42 | 2020 | 10015 | 0.750 |
Why?
|
| Nail Diseases | 2 | 2019 | 6 | 0.740 |
Why?
|
| Aged | 40 | 2020 | 10998 | 0.690 |
Why?
|
| Biopsy | 13 | 2019 | 268 | 0.680 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2019 | 9 | 0.680 |
Why?
|
| Sweet Syndrome | 2 | 2019 | 6 | 0.650 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 54 | 0.650 |
Why?
|
| Langerhans Cells | 1 | 2020 | 2 | 0.640 |
Why?
|
| Keratosis | 2 | 2019 | 23 | 0.630 |
Why?
|
| Cellulitis | 1 | 2019 | 12 | 0.610 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 23 | 0.610 |
Why?
|
| Scalp | 3 | 2020 | 38 | 0.610 |
Why?
|
| Deficiency Diseases | 2 | 2010 | 3 | 0.600 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 20 | 0.600 |
Why?
|
| Zinc | 2 | 2010 | 33 | 0.580 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 2 | 0.580 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 9 | 0.570 |
Why?
|
| Ossification, Heterotopic | 2 | 2009 | 21 | 0.560 |
Why?
|
| Pagetoid Reticulosis | 1 | 2018 | 1 | 0.560 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 352 | 0.550 |
Why?
|
| Coloring Agents | 2 | 2017 | 32 | 0.540 |
Why?
|
| Mast Cells | 2 | 2017 | 13 | 0.540 |
Why?
|
| Fibroma | 3 | 2014 | 12 | 0.540 |
Why?
|
| Certification | 3 | 2009 | 30 | 0.540 |
Why?
|
| Panniculitis, Lupus Erythematosus | 3 | 2014 | 6 | 0.530 |
Why?
|
| Urticaria Pigmentosa | 1 | 2017 | 1 | 0.520 |
Why?
|
| Hemangioma | 4 | 2019 | 24 | 0.520 |
Why?
|
| Pathology, Clinical | 3 | 2018 | 13 | 0.510 |
Why?
|
| Fingers | 3 | 2019 | 78 | 0.510 |
Why?
|
| Hand Dermatoses | 2 | 2016 | 10 | 0.510 |
Why?
|
| Thigh | 2 | 2019 | 43 | 0.470 |
Why?
|
| Hemangiosarcoma | 4 | 2010 | 9 | 0.470 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 4 | 0.460 |
Why?
|
| Treatment Outcome | 9 | 2019 | 3618 | 0.450 |
Why?
|
| Dermatitis | 4 | 2017 | 21 | 0.430 |
Why?
|
| Blood Vessels | 2 | 2009 | 60 | 0.420 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 4150 | 0.420 |
Why?
|
| Histiocytoma, Benign Fibrous | 4 | 2009 | 5 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 196 | 0.410 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2013 | 2 | 0.410 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2013 | 5 | 0.400 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 140 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 399 | 0.370 |
Why?
|
| Parakeratosis | 2 | 2003 | 3 | 0.370 |
Why?
|
| Axilla | 2 | 2003 | 18 | 0.370 |
Why?
|
| Epidermis | 6 | 2020 | 30 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2002 | 46 | 0.360 |
Why?
|
| Keratinocytes | 2 | 2010 | 30 | 0.350 |
Why?
|
| Polycythemia Vera | 1 | 2010 | 2 | 0.340 |
Why?
|
| Paracoccidioidomycosis | 2 | 2009 | 2 | 0.330 |
Why?
|
| Niacin | 1 | 2010 | 7 | 0.330 |
Why?
|
| Acantholysis | 1 | 2010 | 1 | 0.330 |
Why?
|
| Ichthyosis | 1 | 2010 | 1 | 0.330 |
Why?
|
| Giant Cells | 2 | 2009 | 4 | 0.320 |
Why?
|
| Pemphigoid, Bullous | 2 | 2019 | 9 | 0.310 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2009 | 1 | 0.310 |
Why?
|
| Epithelioid Cells | 1 | 2009 | 2 | 0.310 |
Why?
|
| Knee | 2 | 2019 | 31 | 0.310 |
Why?
|
| Desmin | 1 | 2009 | 12 | 0.310 |
Why?
|
| Mycoses | 2 | 2009 | 20 | 0.300 |
Why?
|
| Elbow | 2 | 2019 | 31 | 0.300 |
Why?
|
| Osteoclasts | 1 | 2009 | 25 | 0.300 |
Why?
|
| Fever | 2 | 2019 | 63 | 0.300 |
Why?
|
| Paracoccidioides | 1 | 2009 | 1 | 0.300 |
Why?
|
| Bottle-Nosed Dolphin | 1 | 2009 | 1 | 0.300 |
Why?
|
| Child | 8 | 2017 | 2613 | 0.300 |
Why?
|
| Dermatomyositis | 1 | 2009 | 20 | 0.290 |
Why?
|
| Neoplasms, Vascular Tissue | 3 | 2013 | 7 | 0.280 |
Why?
|
| Lymphoma, B-Cell | 2 | 2002 | 11 | 0.280 |
Why?
|
| Endothelium, Lymphatic | 1 | 2008 | 1 | 0.280 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2008 | 1 | 0.280 |
Why?
|
| Sialoglycoproteins | 1 | 2008 | 8 | 0.280 |
Why?
|
| Keratoacanthoma | 1 | 2008 | 1 | 0.280 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 31 | 0.270 |
Why?
|
| Transglutaminases | 1 | 2007 | 1 | 0.270 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 4 | 0.270 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2366 | 0.260 |
Why?
|
| Acrodermatitis | 1 | 2007 | 1 | 0.260 |
Why?
|
| Arm | 2 | 2017 | 43 | 0.260 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 58 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 922 | 0.260 |
Why?
|
| Carcinoma | 3 | 2013 | 97 | 0.250 |
Why?
|
| Upper Extremity | 3 | 2017 | 68 | 0.240 |
Why?
|
| Hypopigmentation | 3 | 2017 | 7 | 0.240 |
Why?
|
| Hamartoma | 2 | 1997 | 11 | 0.240 |
Why?
|
| Neurilemmoma | 2 | 2005 | 16 | 0.240 |
Why?
|
| Opportunistic Infections | 2 | 2002 | 19 | 0.240 |
Why?
|
| Lower Extremity | 2 | 2017 | 106 | 0.240 |
Why?
|
| Granuloma | 2 | 2002 | 14 | 0.240 |
Why?
|
| Tongue Neoplasms | 2 | 2003 | 5 | 0.230 |
Why?
|
| Specialty Boards | 1 | 2005 | 11 | 0.230 |
Why?
|
| Eyelid Neoplasms | 2 | 2018 | 2 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2019 | 1506 | 0.220 |
Why?
|
| Carcinoma, Basal Cell | 3 | 2014 | 27 | 0.220 |
Why?
|
| Adolescent | 11 | 2013 | 3799 | 0.220 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 318 | 0.220 |
Why?
|
| Education, Medical, Graduate | 3 | 2012 | 138 | 0.220 |
Why?
|
| Dermatomycoses | 2 | 2002 | 7 | 0.220 |
Why?
|
| Eye Neoplasms | 1 | 2004 | 3 | 0.210 |
Why?
|
| Mass Screening | 1 | 2007 | 268 | 0.210 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2004 | 18 | 0.210 |
Why?
|
| Facial Neoplasms | 2 | 2001 | 9 | 0.210 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 803 | 0.210 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 2004 | 7 | 0.210 |
Why?
|
| Remission, Spontaneous | 4 | 2015 | 14 | 0.200 |
Why?
|
| Ganglioneuroma | 1 | 2003 | 2 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2003 | 1 | 0.200 |
Why?
|
| Flow Cytometry | 3 | 2005 | 197 | 0.190 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 24 | 0.190 |
Why?
|
| Fusarium | 1 | 2002 | 2 | 0.190 |
Why?
|
| Fibrosarcoma | 1 | 2002 | 4 | 0.190 |
Why?
|
| Keratosis, Actinic | 2 | 2015 | 20 | 0.190 |
Why?
|
| Lymph Nodes | 2 | 2019 | 120 | 0.190 |
Why?
|
| Prognosis | 6 | 2015 | 1603 | 0.190 |
Why?
|
| Eosinophils | 2 | 2014 | 32 | 0.190 |
Why?
|
| Rare Diseases | 2 | 2019 | 21 | 0.190 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 55 | 0.190 |
Why?
|
| Antigens, CD | 3 | 2009 | 106 | 0.190 |
Why?
|
| Gingival Neoplasms | 1 | 2002 | 1 | 0.180 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2002 | 8 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 40 | 0.180 |
Why?
|
| Periodontitis | 1 | 2002 | 10 | 0.180 |
Why?
|
| Dermoscopy | 2 | 2020 | 12 | 0.180 |
Why?
|
| Neoplasm Proteins | 6 | 2009 | 155 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2002 | 19 | 0.180 |
Why?
|
| Precancerous Conditions | 2 | 2013 | 26 | 0.180 |
Why?
|
| Carcinoma, Skin Appendage | 1 | 2001 | 1 | 0.180 |
Why?
|
| Darier Disease | 1 | 2001 | 2 | 0.170 |
Why?
|
| Antigens, Neoplasm | 4 | 2009 | 44 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1993 | 259 | 0.170 |
Why?
|
| Hyperpigmentation | 2 | 2013 | 17 | 0.170 |
Why?
|
| Toes | 2 | 2017 | 18 | 0.170 |
Why?
|
| Endothelium, Vascular | 4 | 2009 | 163 | 0.170 |
Why?
|
| Glomus Tumor | 2 | 2017 | 5 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2006 | 251 | 0.160 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2000 | 2 | 0.160 |
Why?
|
| Scalp Dermatoses | 1 | 2020 | 18 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 36 | 0.160 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 32 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2000 | 34 | 0.160 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 176 | 0.160 |
Why?
|
| Alopecia | 1 | 2020 | 31 | 0.160 |
Why?
|
| Dermis | 5 | 2009 | 18 | 0.160 |
Why?
|
| Tibial Nerve | 1 | 2020 | 22 | 0.160 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 934 | 0.160 |
Why?
|
| Sural Nerve | 1 | 2020 | 28 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2000 | 80 | 0.160 |
Why?
|
| Taxoids | 1 | 2020 | 60 | 0.160 |
Why?
|
| Streptococcus | 1 | 2019 | 8 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 11 | 0.150 |
Why?
|
| Acrospiroma | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2019 | 8 | 0.150 |
Why?
|
| Foot Diseases | 1 | 2019 | 12 | 0.150 |
Why?
|
| Median Nerve | 1 | 2020 | 53 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 54 | 0.150 |
Why?
|
| S100 Proteins | 4 | 2005 | 19 | 0.150 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 1999 | 2 | 0.150 |
Why?
|
| Eccrine Glands | 2 | 1997 | 2 | 0.150 |
Why?
|
| Arteriovenous Fistula | 1 | 1999 | 19 | 0.150 |
Why?
|
| Retrospective Studies | 7 | 2011 | 3812 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 29 | 0.150 |
Why?
|
| Actinomycosis | 1 | 1998 | 2 | 0.140 |
Why?
|
| Oral Ulcer | 1 | 1998 | 5 | 0.140 |
Why?
|
| Antigens, CD7 | 1 | 2018 | 4 | 0.140 |
Why?
|
| Palate | 1 | 1998 | 4 | 0.140 |
Why?
|
| Bone Marrow Examination | 1 | 2018 | 7 | 0.140 |
Why?
|
| Chondroma | 1 | 2018 | 4 | 0.140 |
Why?
|
| Vascular Neoplasms | 3 | 2009 | 12 | 0.140 |
Why?
|
| Nevus | 2 | 2004 | 17 | 0.140 |
Why?
|
| Vulvar Neoplasms | 2 | 2013 | 8 | 0.140 |
Why?
|
| Infant | 6 | 2019 | 1122 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2013 | 1354 | 0.140 |
Why?
|
| Foot | 1 | 2018 | 42 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 115 | 0.130 |
Why?
|
| Prednisone | 3 | 2008 | 70 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2020 | 417 | 0.130 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2017 | 1 | 0.130 |
Why?
|
| Eyelids | 1 | 2017 | 8 | 0.130 |
Why?
|
| Lacrimal Apparatus | 1 | 2017 | 4 | 0.130 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2017 | 14 | 0.130 |
Why?
|
| Conjunctiva | 1 | 2017 | 5 | 0.130 |
Why?
|
| Angiomyoma | 1 | 2017 | 3 | 0.130 |
Why?
|
| Conjunctival Diseases | 1 | 2017 | 4 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2008 | 212 | 0.130 |
Why?
|
| Nerve Fibers | 2 | 2020 | 40 | 0.130 |
Why?
|
| Myxedema | 1 | 1996 | 3 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 627 | 0.120 |
Why?
|
| Skin Pigmentation | 1 | 2017 | 27 | 0.120 |
Why?
|
| Cladribine | 1 | 1996 | 3 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2013 | 484 | 0.120 |
Why?
|
| Scleroderma, Systemic | 1 | 1996 | 7 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 5 | 2004 | 56 | 0.120 |
Why?
|
| Terminology as Topic | 2 | 1993 | 71 | 0.120 |
Why?
|
| Sparganosis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Sparganum | 1 | 2016 | 1 | 0.120 |
Why?
|
| Skin Diseases, Infectious | 1 | 2016 | 2 | 0.120 |
Why?
|
| Zoonoses | 1 | 2016 | 6 | 0.120 |
Why?
|
| Leg | 2 | 2020 | 71 | 0.120 |
Why?
|
| Hyperplasia | 4 | 2013 | 42 | 0.120 |
Why?
|
| Antinematodal Agents | 1 | 2015 | 1 | 0.120 |
Why?
|
| Skin Diseases, Parasitic | 1 | 2015 | 1 | 0.120 |
Why?
|
| Nematoda | 1 | 2015 | 2 | 0.120 |
Why?
|
| Nematode Infections | 1 | 2015 | 2 | 0.120 |
Why?
|
| Telemedicine | 1 | 2017 | 120 | 0.120 |
Why?
|
| Sarcoma, Kaposi | 3 | 2002 | 9 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 502 | 0.120 |
Why?
|
| Hidradenitis | 1 | 1995 | 1 | 0.110 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1995 | 6 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 9 | 0.110 |
Why?
|
| Herpes Simplex | 1 | 1995 | 14 | 0.110 |
Why?
|
| Herpes Zoster | 1 | 1995 | 12 | 0.110 |
Why?
|
| Radiography | 3 | 2019 | 397 | 0.110 |
Why?
|
| Administration, Topical | 2 | 2007 | 146 | 0.110 |
Why?
|
| Hemochromatosis | 1 | 1995 | 70 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 489 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 515 | 0.110 |
Why?
|
| Liver Diseases | 1 | 1995 | 75 | 0.110 |
Why?
|
| Rhinophyma | 1 | 1994 | 2 | 0.110 |
Why?
|
| Pruritus | 1 | 2014 | 47 | 0.110 |
Why?
|
| Mohs Surgery | 2 | 2007 | 16 | 0.110 |
Why?
|
| African Americans | 1 | 2001 | 1435 | 0.110 |
Why?
|
| Europe | 3 | 2016 | 86 | 0.110 |
Why?
|
| Chordoma | 1 | 1994 | 7 | 0.110 |
Why?
|
| Education, Medical, Continuing | 2 | 2012 | 58 | 0.100 |
Why?
|
| Infrared Rays | 1 | 2013 | 20 | 0.100 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2013 | 14 | 0.100 |
Why?
|
| Leishmaniasis, Mucocutaneous | 1 | 1993 | 1 | 0.100 |
Why?
|
| Wrestling | 1 | 1993 | 2 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 589 | 0.100 |
Why?
|
| Tinea | 1 | 1993 | 5 | 0.100 |
Why?
|
| Calcinosis | 1 | 2014 | 150 | 0.100 |
Why?
|
| Penile Neoplasms | 2 | 2004 | 6 | 0.100 |
Why?
|
| Dysplastic Nevus Syndrome | 1 | 1993 | 2 | 0.100 |
Why?
|
| Disease Outbreaks | 1 | 1993 | 44 | 0.100 |
Why?
|
| Contrast Media | 2 | 2007 | 148 | 0.100 |
Why?
|
| PUVA Therapy | 2 | 2009 | 22 | 0.090 |
Why?
|
| Back | 2 | 2010 | 4 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 1992 | 24 | 0.090 |
Why?
|
| Glucocorticoids | 3 | 2009 | 154 | 0.090 |
Why?
|
| Myoepithelioma | 2 | 2003 | 2 | 0.090 |
Why?
|
| Lymphoma | 1 | 1992 | 40 | 0.090 |
Why?
|
| Pain | 1 | 2014 | 330 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2010 | 59 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 485 | 0.090 |
Why?
|
| Pregnancy | 1 | 2015 | 1069 | 0.090 |
Why?
|
| Phenotype | 1 | 2013 | 656 | 0.090 |
Why?
|
| Eczema | 1 | 2011 | 14 | 0.090 |
Why?
|
| Histiocytes | 2 | 2009 | 3 | 0.090 |
Why?
|
| Groin | 1 | 2010 | 5 | 0.080 |
Why?
|
| Inflammation | 1 | 2014 | 557 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 230 | 0.080 |
Why?
|
| Lymphangioma | 2 | 2002 | 7 | 0.080 |
Why?
|
| DNA | 1 | 1992 | 235 | 0.080 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2010 | 2 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 849 | 0.080 |
Why?
|
| Governing Board | 1 | 2009 | 1 | 0.080 |
Why?
|
| Paget's Disease, Mammary | 2 | 2002 | 3 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2009 | 63 | 0.080 |
Why?
|
| Fibrosis | 2 | 2007 | 129 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 76 | 0.080 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Actins | 1 | 2009 | 56 | 0.080 |
Why?
|
| Histiocytosis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Lymphatic Vessels | 1 | 2009 | 7 | 0.080 |
Why?
|
| Clobetasol | 1 | 2009 | 27 | 0.070 |
Why?
|
| Brazil | 1 | 2009 | 16 | 0.070 |
Why?
|
| Renal Dialysis | 2 | 2003 | 282 | 0.070 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.070 |
Why?
|
| Purpura | 2 | 1999 | 4 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 103 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2008 | 1 | 0.070 |
Why?
|
| Granuloma Annulare | 1 | 2008 | 2 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2007 | 509 | 0.070 |
Why?
|
| Lymphangiectasis | 2 | 1999 | 5 | 0.070 |
Why?
|
| Lip | 1 | 2008 | 7 | 0.070 |
Why?
|
| Melanocytes | 3 | 2001 | 8 | 0.070 |
Why?
|
| Neurothekeoma | 1 | 2008 | 2 | 0.070 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 150 | 0.070 |
Why?
|
| Elastic Tissue | 1 | 2007 | 2 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 203 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Factor XIIIa | 1 | 2007 | 2 | 0.070 |
Why?
|
| Atrophy | 1 | 2007 | 51 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 21 | 0.070 |
Why?
|
| Gadolinium | 1 | 2007 | 22 | 0.070 |
Why?
|
| Methotrexate | 1 | 2008 | 71 | 0.070 |
Why?
|
| Syndrome | 1 | 2007 | 76 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 101 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2007 | 120 | 0.060 |
Why?
|
| Extremities | 1 | 2007 | 55 | 0.060 |
Why?
|
| Career Choice | 1 | 2007 | 45 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2007 | 62 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2007 | 56 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 88 | 0.060 |
Why?
|
| Family Practice | 1 | 2007 | 49 | 0.060 |
Why?
|
| Germany | 1 | 2006 | 7 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 168 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2006 | 12 | 0.060 |
Why?
|
| Polychondritis, Relapsing | 1 | 2006 | 2 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 214 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 270 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 49 | 0.060 |
Why?
|
| Mycophenolic Acid | 1 | 2006 | 42 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 1386 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1607 | 0.060 |
Why?
|
| Dilatation, Pathologic | 2 | 2013 | 20 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 35 | 0.060 |
Why?
|
| Animals | 3 | 2016 | 8544 | 0.060 |
Why?
|
| Nevus, Blue | 2 | 2002 | 3 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2007 | 924 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2005 | 32 | 0.060 |
Why?
|
| Necrosis | 2 | 1995 | 54 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 104 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2008 | 87 | 0.050 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2004 | 2 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 124 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 565 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 135 | 0.050 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2003 | 1 | 0.050 |
Why?
|
| Genes, Retinoblastoma | 1 | 2003 | 2 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 1995 | 119 | 0.050 |
Why?
|
| Neurofilament Proteins | 1 | 2003 | 17 | 0.050 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2003 | 44 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2003 | 12 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2003 | 15 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 44 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2003 | 11 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2003 | 68 | 0.050 |
Why?
|
| Actinomycetales | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lip Neoplasms | 1 | 2002 | 2 | 0.050 |
Why?
|
| Syphilis, Cutaneous | 1 | 2002 | 2 | 0.050 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2002 | 2 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 2002 | 4 | 0.050 |
Why?
|
| Corynebacterium Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2002 | 4 | 0.050 |
Why?
|
| Angiomatosis | 1 | 2002 | 4 | 0.050 |
Why?
|
| Nevus, Pigmented | 1 | 2002 | 6 | 0.050 |
Why?
|
| Forearm | 2 | 2020 | 49 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2005 | 628 | 0.050 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2002 | 13 | 0.050 |
Why?
|
| Adenoma | 1 | 2002 | 36 | 0.050 |
Why?
|
| Pigmentation Disorders | 1 | 2002 | 8 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 2461 | 0.040 |
Why?
|
| Neutrophils | 1 | 2002 | 122 | 0.040 |
Why?
|
| Sarcoidosis | 2 | 2002 | 33 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2005 | 330 | 0.040 |
Why?
|
| Dermatitis, Atopic | 1 | 2002 | 103 | 0.040 |
Why?
|
| Disease Progression | 2 | 2015 | 633 | 0.040 |
Why?
|
| Keratins | 2 | 1998 | 42 | 0.040 |
Why?
|
| Ankle | 1 | 2020 | 32 | 0.040 |
Why?
|
| Albumins | 1 | 2020 | 47 | 0.040 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 42 | 0.040 |
Why?
|
| Wrist | 1 | 2020 | 50 | 0.040 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1999 | 2 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 73 | 0.040 |
Why?
|
| Forefoot, Human | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2019 | 22 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2019 | 69 | 0.040 |
Why?
|
| Psoriasis | 1 | 2004 | 362 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 92 | 0.040 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1999 | 1 | 0.040 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 1999 | 2 | 0.040 |
Why?
|
| Panniculitis | 1 | 1999 | 3 | 0.040 |
Why?
|
| Collagen Diseases | 1 | 1999 | 5 | 0.040 |
Why?
|
| Skin Diseases, Viral | 1 | 1999 | 4 | 0.040 |
Why?
|
| Skin Diseases, Genetic | 1 | 1999 | 4 | 0.040 |
Why?
|
| Vasculitis | 1 | 1999 | 26 | 0.040 |
Why?
|
| Graft vs Host Disease | 1 | 1999 | 28 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 68 | 0.040 |
Why?
|
| Diatrizoate Meglumine | 1 | 1998 | 1 | 0.040 |
Why?
|
| Hyperkeratosis, Epidermolytic | 1 | 1998 | 1 | 0.040 |
Why?
|
| Drug Eruptions | 1 | 1998 | 9 | 0.030 |
Why?
|
| Registries | 2 | 2010 | 328 | 0.030 |
Why?
|
| Angiolipoma | 1 | 1998 | 1 | 0.030 |
Why?
|
| Angiofibroma | 1 | 1998 | 2 | 0.030 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 1998 | 3 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1998 | 5 | 0.030 |
Why?
|
| Angiomyolipoma | 1 | 1998 | 5 | 0.030 |
Why?
|
| Myxoma | 1 | 1998 | 5 | 0.030 |
Why?
|
| Software | 1 | 2018 | 130 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 583 | 0.030 |
Why?
|
| Angiomatosis, Bacillary | 1 | 1997 | 1 | 0.030 |
Why?
|
| Hemangioma, Cavernous | 1 | 1997 | 3 | 0.030 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 1997 | 3 | 0.030 |
Why?
|
| Granuloma, Pyogenic | 1 | 1997 | 5 | 0.030 |
Why?
|
| Hemangioma, Capillary | 1 | 1997 | 3 | 0.030 |
Why?
|
| Hemangiopericytoma | 1 | 1997 | 6 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 984 | 0.030 |
Why?
|
| Angiokeratoma | 1 | 1997 | 2 | 0.030 |
Why?
|
| Venules | 1 | 1997 | 5 | 0.030 |
Why?
|
| Lymphatic System | 1 | 1997 | 3 | 0.030 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 1997 | 9 | 0.030 |
Why?
|
| Cell Lineage | 1 | 1997 | 71 | 0.030 |
Why?
|
| Veins | 1 | 1997 | 35 | 0.030 |
Why?
|
| Acute Disease | 1 | 1998 | 276 | 0.030 |
Why?
|
| Capillaries | 1 | 1997 | 30 | 0.030 |
Why?
|
| Aneurysm | 1 | 1997 | 21 | 0.030 |
Why?
|
| Oculomotor Muscles | 1 | 1997 | 5 | 0.030 |
Why?
|
| Eye Diseases | 1 | 1997 | 5 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 108 | 0.030 |
Why?
|
| Melanins | 1 | 1996 | 7 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2009 | 74 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 323 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1996 | 31 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 110 | 0.030 |
Why?
|
| Praziquantel | 1 | 2016 | 2 | 0.030 |
Why?
|
| Seawater | 1 | 2016 | 3 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 14 | 0.030 |
Why?
|
| Anthelmintics | 1 | 2016 | 3 | 0.030 |
Why?
|
| Helminthiasis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Helminths | 1 | 2015 | 1 | 0.030 |
Why?
|
| Tropical Climate | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endemic Diseases | 1 | 2015 | 4 | 0.030 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2010 | 3 | 0.030 |
Why?
|
| Glucagonoma | 1 | 1995 | 1 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 1995 | 2 | 0.030 |
Why?
|
| Inclusion Bodies, Viral | 1 | 1995 | 4 | 0.030 |
Why?
|
| Tongue Diseases | 1 | 1995 | 4 | 0.030 |
Why?
|
| Hair Follicle | 1 | 1995 | 8 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1995 | 31 | 0.030 |
Why?
|
| Chromatin | 1 | 1995 | 28 | 0.030 |
Why?
|
| Edema | 1 | 1995 | 31 | 0.030 |
Why?
|
| Young Adult | 2 | 2013 | 2825 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1995 | 57 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 1999 | 548 | 0.030 |
Why?
|
| Facial Dermatoses | 1 | 1994 | 18 | 0.030 |
Why?
|
| Dental Instruments | 1 | 1993 | 1 | 0.030 |
Why?
|
| Nails | 1 | 1993 | 6 | 0.030 |
Why?
|
| Onychomycosis | 1 | 1993 | 8 | 0.030 |
Why?
|
| Curettage | 1 | 1993 | 10 | 0.030 |
Why?
|
| Leishmaniasis, Diffuse Cutaneous | 1 | 1993 | 1 | 0.030 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 1993 | 2 | 0.030 |
Why?
|
| Bolivia | 1 | 1993 | 3 | 0.030 |
Why?
|
| Specimen Handling | 1 | 1993 | 33 | 0.020 |
Why?
|
| Diploidy | 1 | 1993 | 3 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 385 | 0.020 |
Why?
|
| Microscopy | 1 | 1993 | 28 | 0.020 |
Why?
|
| Vascular Malformations | 1 | 2013 | 11 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 1992 | 4 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1992 | 24 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 12 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 1993 | 45 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1992 | 51 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 1992 | 6 | 0.020 |
Why?
|
| Credentialing | 1 | 2012 | 9 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 43 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 84 | 0.020 |
Why?
|
| Wilms Tumor | 1 | 1992 | 15 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2012 | 54 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1288 | 0.020 |
Why?
|
| Ploidies | 1 | 1992 | 7 | 0.020 |
Why?
|
| Aneuploidy | 1 | 1992 | 11 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1034 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2011 | 9 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2012 | 122 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 190 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 168 | 0.020 |
Why?
|
| Austria | 1 | 2010 | 3 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 155 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 90 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2009 | 19 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 25 | 0.020 |
Why?
|
| Eyelid Diseases | 1 | 2009 | 3 | 0.020 |
Why?
|
| Phosphoglucomutase | 1 | 2009 | 5 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2009 | 54 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 612 | 0.020 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Fluocinonide | 1 | 2008 | 11 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 19 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 118 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 304 | 0.020 |
Why?
|
| Azacitidine | 1 | 2008 | 29 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 50 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2352 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1910 | 0.020 |
Why?
|
| Perineum | 1 | 2006 | 18 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 730 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 26 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 4136 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 46 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 328 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2005 | 91 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 400 | 0.010 |
Why?
|
| Leprosy | 1 | 2002 | 2 | 0.010 |
Why?
|
| Neurofibroma | 1 | 2002 | 2 | 0.010 |
Why?
|
| Leishmaniasis | 1 | 2002 | 3 | 0.010 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 2002 | 5 | 0.010 |
Why?
|
| Germinal Center | 1 | 2002 | 5 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 772 | 0.010 |
Why?
|
| Clone Cells | 1 | 2002 | 37 | 0.010 |
Why?
|
| Salivary Glands, Minor | 1 | 2002 | 10 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 231 | 0.010 |
Why?
|
| HIV-1 | 1 | 2002 | 46 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 350 | 0.010 |
Why?
|
| Breast | 1 | 2002 | 68 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 491 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 273 | 0.010 |
Why?
|
| Pedigree | 1 | 1999 | 142 | 0.010 |
Why?
|
| Breast Neoplasms, Male | 1 | 1999 | 11 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1999 | 40 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1999 | 56 | 0.010 |
Why?
|
| Hysterosalpingography | 1 | 1998 | 1 | 0.010 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1998 | 8 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 44 | 0.010 |
Why?
|
| Depth Perception | 1 | 1997 | 1 | 0.010 |
Why?
|
| Eye Movements | 1 | 1997 | 16 | 0.010 |
Why?
|
| Visual Acuity | 1 | 1997 | 76 | 0.010 |
Why?
|
| United States | 1 | 2005 | 4267 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1999 | 317 | 0.010 |
Why?
|
| Griseofulvin | 1 | 1993 | 1 | 0.010 |
Why?
|
| Ketoconazole | 1 | 1993 | 5 | 0.010 |
Why?
|
| Itraconazole | 1 | 1993 | 6 | 0.010 |
Why?
|
| Fluconazole | 1 | 1993 | 8 | 0.010 |
Why?
|
| Molecular Structure | 1 | 1993 | 60 | 0.010 |
Why?
|